Medicine
Nemluvio 30 mg/100 mg powder for injection
Nemluvio 30 mg/100 mg powder for injection is a prescription medicine containing Nemolizumab for subcutaneous use, marketed by Galderma Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store the NEMLUVIO dual-chamber, prefilled pen in a refrigerator at 36°F to…
Key facts
- Active ingredient (INN)
- Nemolizumab
- Brand
- Nemluvio
- Strength
- 30 mg/100 mg
- Dosage form
- Powder for injection
- Route
- Subcutaneous
- Packs
- 1 syringe
- Marketing authorisation holder
- Galderma Laboratories
- Manufacturer
- Galderma Laboratories
- Origin register
- US FDA, United States
- Storage
- Store the NEMLUVIO dual-chamber, prefilled pen in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light until the expiration date. Do not freeze. Alternatively, the NEMLUVIO carton containing the unused dual-chamber, prefilled pen may be stored at room temperature [up to 77°F (25°C)] for up to 90 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AH12 Nemolizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 August 2024
- Identifiers
- RxCUI 2691325, 2691328DailyMed set ID e9229ef1-ac60-4c24-afb6-009d3c781687NDC 0299-6220Application BLA761390
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / 30 mg in 1 syringe | 0299-6220-15 | Galderma Laboratories | 13 August 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Nemolizumab is an interleukin-31 receptor alpha antagonist indicated for prurigo Nodularis The treatment of adults with prurigo nodularis, among other approved uses. It is available as powder for injection for subcutaneous use. MedsAcross supplies Nemolizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NemolizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NEMLUVIO prescribing information (Galderma Laboratories) · U.S. National Library of Medicine, DailyMed
- Nemluvio: European public assessment report (EPAR) · European Medicines Agency
Need Nemluvio 30 mg/100 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.